Warner Chilcott PLC

Biopharma executives and outside counsel honed in on several issues that could impact the way companies promote their medical products at the Food and Drug Law Institute’s advertising and promotion co

For biopharma companies, the past decade was filled with momentous events in the legal realm, from creation of a new way to challenge patents to the emergence of biosimilar litigation and generic pric

As Rep. Jan Schakowsky, D-Ill, plans to introduce a bill targeted at brand manufacturer product hopping, legal experts offered advice on how to assure it is not too broad or vague as to interfere with

Concern about drug prices are one of the last issues of bipartisan agreement these days, so it should not come as a surprise that the flurry of activity on the topic this year might threaten even the